An overview of current and future therapeutic strategies for the treatment of primary sclerosing cholangitis

Ahmad H. Ali, Elizabeth J. Carey, Keith D. Lindor

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Primary sclerosing cholangitis (PCS) is a cholestatic liver disease characterized by chronic destruction and stricturing of the biliary tree, leading to fibrosis and liver cirrhosis. The underlying mechanisms of the disease are poorly understood. Areas covered: Multiple agents with various pharmacological activities have been examined in PSC patients with disappointing results. Ursodeoxycholic acid (UDCA) is by far the most extensively studied agent in PSC. Large prospective trials have failed to demonstrate a positive long-term effect of UDCA in patients with PSC. Antimicrobials have been examined in PSC patients but long-term outcome data are lacking. Immunosuppressive agents were tested in patients with PSC but the majority of these agents were associated with adverse side effects. Nor-UDCA is a newly emerging C23 homolog of UDCA that has shown promising results in experimental studies. The farnesoid X receptor agonists are an attractive class of drugs and are currently being studied in patients with primary biliary cirrhosis. Antifibrotic agents have yielded encouraging results in animal models of PSC but are yet to be evaluated in humans. Expert opinion: Currently, there is no effective treatment for PSC. It is our hope that the newly discovered potential therapeutic routes will lead to the discovery of a curative agent for this debilitating disease.

Original languageEnglish (US)
Pages (from-to)545-556
Number of pages12
JournalExpert Opinion on Orphan Drugs
Volume2
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Sclerosing Cholangitis
Ursodeoxycholic Acid
Therapeutics
Biliary Liver Cirrhosis
Expert Testimony
Biliary Tract
Immunosuppressive Agents
Liver Cirrhosis
Liver Diseases
Fibrosis
Animal Models
Pharmacology
Pharmaceutical Preparations

Keywords

  • Antimicrobial
  • Farnesoid x receptor
  • Primary sclerosing cholangitis
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

An overview of current and future therapeutic strategies for the treatment of primary sclerosing cholangitis. / Ali, Ahmad H.; Carey, Elizabeth J.; Lindor, Keith D.

In: Expert Opinion on Orphan Drugs, Vol. 2, No. 6, 2014, p. 545-556.

Research output: Contribution to journalArticle

Ali, Ahmad H. ; Carey, Elizabeth J. ; Lindor, Keith D. / An overview of current and future therapeutic strategies for the treatment of primary sclerosing cholangitis. In: Expert Opinion on Orphan Drugs. 2014 ; Vol. 2, No. 6. pp. 545-556.
@article{6d73a7a043a3443dbfb5a62473ead9c5,
title = "An overview of current and future therapeutic strategies for the treatment of primary sclerosing cholangitis",
abstract = "Introduction: Primary sclerosing cholangitis (PCS) is a cholestatic liver disease characterized by chronic destruction and stricturing of the biliary tree, leading to fibrosis and liver cirrhosis. The underlying mechanisms of the disease are poorly understood. Areas covered: Multiple agents with various pharmacological activities have been examined in PSC patients with disappointing results. Ursodeoxycholic acid (UDCA) is by far the most extensively studied agent in PSC. Large prospective trials have failed to demonstrate a positive long-term effect of UDCA in patients with PSC. Antimicrobials have been examined in PSC patients but long-term outcome data are lacking. Immunosuppressive agents were tested in patients with PSC but the majority of these agents were associated with adverse side effects. Nor-UDCA is a newly emerging C23 homolog of UDCA that has shown promising results in experimental studies. The farnesoid X receptor agonists are an attractive class of drugs and are currently being studied in patients with primary biliary cirrhosis. Antifibrotic agents have yielded encouraging results in animal models of PSC but are yet to be evaluated in humans. Expert opinion: Currently, there is no effective treatment for PSC. It is our hope that the newly discovered potential therapeutic routes will lead to the discovery of a curative agent for this debilitating disease.",
keywords = "Antimicrobial, Farnesoid x receptor, Primary sclerosing cholangitis, Ursodeoxycholic acid",
author = "Ali, {Ahmad H.} and Carey, {Elizabeth J.} and Lindor, {Keith D.}",
year = "2014",
doi = "10.1517/21678707.2014.908701",
language = "English (US)",
volume = "2",
pages = "545--556",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - An overview of current and future therapeutic strategies for the treatment of primary sclerosing cholangitis

AU - Ali, Ahmad H.

AU - Carey, Elizabeth J.

AU - Lindor, Keith D.

PY - 2014

Y1 - 2014

N2 - Introduction: Primary sclerosing cholangitis (PCS) is a cholestatic liver disease characterized by chronic destruction and stricturing of the biliary tree, leading to fibrosis and liver cirrhosis. The underlying mechanisms of the disease are poorly understood. Areas covered: Multiple agents with various pharmacological activities have been examined in PSC patients with disappointing results. Ursodeoxycholic acid (UDCA) is by far the most extensively studied agent in PSC. Large prospective trials have failed to demonstrate a positive long-term effect of UDCA in patients with PSC. Antimicrobials have been examined in PSC patients but long-term outcome data are lacking. Immunosuppressive agents were tested in patients with PSC but the majority of these agents were associated with adverse side effects. Nor-UDCA is a newly emerging C23 homolog of UDCA that has shown promising results in experimental studies. The farnesoid X receptor agonists are an attractive class of drugs and are currently being studied in patients with primary biliary cirrhosis. Antifibrotic agents have yielded encouraging results in animal models of PSC but are yet to be evaluated in humans. Expert opinion: Currently, there is no effective treatment for PSC. It is our hope that the newly discovered potential therapeutic routes will lead to the discovery of a curative agent for this debilitating disease.

AB - Introduction: Primary sclerosing cholangitis (PCS) is a cholestatic liver disease characterized by chronic destruction and stricturing of the biliary tree, leading to fibrosis and liver cirrhosis. The underlying mechanisms of the disease are poorly understood. Areas covered: Multiple agents with various pharmacological activities have been examined in PSC patients with disappointing results. Ursodeoxycholic acid (UDCA) is by far the most extensively studied agent in PSC. Large prospective trials have failed to demonstrate a positive long-term effect of UDCA in patients with PSC. Antimicrobials have been examined in PSC patients but long-term outcome data are lacking. Immunosuppressive agents were tested in patients with PSC but the majority of these agents were associated with adverse side effects. Nor-UDCA is a newly emerging C23 homolog of UDCA that has shown promising results in experimental studies. The farnesoid X receptor agonists are an attractive class of drugs and are currently being studied in patients with primary biliary cirrhosis. Antifibrotic agents have yielded encouraging results in animal models of PSC but are yet to be evaluated in humans. Expert opinion: Currently, there is no effective treatment for PSC. It is our hope that the newly discovered potential therapeutic routes will lead to the discovery of a curative agent for this debilitating disease.

KW - Antimicrobial

KW - Farnesoid x receptor

KW - Primary sclerosing cholangitis

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=84901339291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901339291&partnerID=8YFLogxK

U2 - 10.1517/21678707.2014.908701

DO - 10.1517/21678707.2014.908701

M3 - Article

AN - SCOPUS:84901339291

VL - 2

SP - 545

EP - 556

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 6

ER -